AlloVir, Inc. (NASDAQ:ALVR) Holdings Lowered by Acadian Asset Management LLC

Acadian Asset Management LLC lowered its stake in AlloVir, Inc. (NASDAQ:ALVR) by 25.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,175,954 shares of the company’s stock after selling 411,497 shares during the quarter. Acadian Asset Management LLC owned approximately 1.02% of AlloVir worth $850,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Pennant Investors LP purchased a new position in shares of AlloVir in the fourth quarter worth approximately $147,000. Twin Focus Capital Partners LLC purchased a new position in AlloVir during the 4th quarter worth approximately $40,000. Marquette Asset Management LLC acquired a new stake in AlloVir during the 1st quarter valued at $135,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of AlloVir by 127.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock valued at $74,000 after purchasing an additional 54,900 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Trading Up 1.0 %

Shares of ALVR stock opened at $0.76 on Tuesday. The company has a market capitalization of $87.40 million, a price-to-earnings ratio of -0.46 and a beta of 0.78. AlloVir, Inc. has a 1-year low of $0.58 and a 1-year high of $2.54. The stock’s fifty day simple moving average is $0.76 and its 200-day simple moving average is $0.76.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. On average, sell-side analysts predict that AlloVir, Inc. will post -0.5 EPS for the current year.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.